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A B S T R A C T
Background
The provision of highly active antiretroviral therapy (HAART) in resource-limited settings
follows a public health approach, which is characterised by a limited number of regimens and
the standardisation of clinical and laboratory monitoring. In industrialized countries doctors
prescribe from the full range of available antiretroviral drugs, supported by resistance testing
and frequent laboratory monitoring. We compared virologic response, changes to first-line
regimens, and mortality in HIV-infected patients starting HAART in South Africa and
Switzerland.
Methods and Findings
We analysed data from the Swiss HIV Cohort Study and two HAART programmes in
townships of Cape Town, South Africa. We included treatment-naı¨ve patients aged 16 y or
older who had started treatment with at least three drugs since 2001, and excluded
intravenous drug users. Data from a total of 2,348 patients from South Africa and 1,016 patients
from the Swiss HIV Cohort Study were analysed. Median baseline CD4þ T cell counts were 80
cells/ll in South Africa and 204 cells/ll in Switzerland. In South Africa, patients started with one
of four first-line regimens, which was subsequently changed in 514 patients (22%). In
Switzerland, 36 first-line regimens were used initially, and these were changed in 539 patients
(53%). In most patients HIV-1 RNA was suppressed to 500 copies/ml or less within one year:
96% (95% confidence interval [CI] 95%–97%) in South Africa and 96% (94%–97%) in
Switzerland, and 26% (22%–29%) and 27% (24%–31%), respectively, developed viral rebound
within two years. Mortality was higher in South Africa than in Switzerland during the first
months of HAART: adjusted hazard ratios were 5.90 (95% CI 1.81–19.2) during months 1–3 and
1.77 (0.90–3.50) during months 4–24.
Conclusions
Compared to the highly individualised approach in Switzerland, programmatic HAART in
South Africa resulted in similar virologic outcomes, with relatively few changes to initial
regimens. Further innovation and resources are required in South Africa to both achieve more
timely access to HAART and improve the prognosis of patients who start HAART with advanced
disease.
The Editors’ Summary of this article follows the references.
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Introduction
The introduction of highly active antiretroviral combina-
tion therapy (HAART) since 1996 has substantially improved
the prognosis of HIV-infected patients in industrialized
countries [1]. Only few drugs were available initially, but
today over 20 approved antiretroviral drugs from four drug
classes are available, including nucleoside reverse transcrip-
tase inhibitors (NRTIs), non-nucleoside reverse transcriptase
inhibitors (NNRTIs), protease inhibitors (PIs), and fusion
inhibitors. In industrialized countries doctors prescribe from
the full range of available antiretroviral drugs. Resistance
testing and frequent monitoring of CD4 cell counts and viral
load are used to individually tailor drug regimens.
In contrast, based on the experience of treating tuber-
culosis, the World Health Organization (WHO) has developed
a public-health approach to providing HAART in resource-
limited settings. This approach takes the realities of weak
health systems into account, including the level of training of
health-care workers, the high patient burden, limited avail-
ability of drugs, and the experience of pilot programmes [2,3].
Key characteristics of this public-health approach include the
standardisation of first-line and second-line regimens, sim-
plified clinical decision-making, and standardised clinical and
laboratory monitoring [3]. The choice of regimens in these
programs is determined primarily by cost and ease of
administration and can include drugs that are no longer
widely used in industrialized countries. Viral load monitoring
is not considered essential, and individual drug resistance
testing is generally not available. A survey of national
guidelines developed by 43 low- and middle-income countries
showed that the public-health approach to antiretroviral
therapy has been widely adopted in these countries [4]. An
estimated 2 million people living with HIV/AIDS were
receiving treatment in low- and middle-income countries by
December 2006, representing 28% of the estimated 7.1
million people in urgent need of treatment at that time [5].
We compared the public-health and individual approach to
HAART by analysing virologic response, changes to first-line
regimens, and mortality in patients starting HAART in
Switzerland and two townships in Cape Town, South Africa.
Methods
We analysed data from the Khayelitsha and Gugulethu
HAART programmes in the Republic of South Africa, which
are part of the International Epidemiological Databases to
Evaluate AIDS in Southern Africa (IeDEA-SA), and made
comparisons with the Swiss HIV Cohort Study (SHCS).
Khayelitsha and Gugulethu Cohorts, Cape Town, South
Africa
Khayelitsha and Gugulethu are townships located within
the Cape Town metropolitan area with estimated populations
of 400,000 and 300,000 people, respectively. Khayelitsha had,
in 1999, the first routine government-run programme for the
prevention of mother-to-child transmission of HIV in South
Africa. Antiretroviral treatment has been available since 2001
at three government clinics providing HIV care, supported by
Me´decins Sans Frontie`res. In Gugulethu the Usaphu Luwethu
(‘‘Our Family Clinic’’) antiretroviral treatment programme
was initiated by the Desmond Tutu HIV Centre in September
2002. Ten primary-care HIV clinics form the patient referral
base.
Enrolment into treatment programmes follows the South
African government’s Department of Health national guide-
lines, which are based on the 2002 WHO recommendations
[6]. Individuals are eligible for treatment if they are in WHO
stage 4 (with the exception of extrapulmonary tuberculosis,
which is a stage 4–defining illness but not a criterion for
starting therapy in the Western Cape) or have a CD4 count
below 200 cells/ll. Data are collected prospectively using
structured records completed at each consultation, including
information on WHO stage-defining illnesses [7].
In Khayelitsha, viral load assessments are performed
routinely before starting HAART, after 3 mo, and then every
6 mo. In Gugulethu viral load is assessed before starting
HAART and every 4-mo thereafter. Plasma viral load was
measured using a branch DNA hybridization technique
(Bayer HIV-1 RNA 3.0 assay, Leverkusen, Germany) or nucleic
acid sequence-based amplification (Nuclisens EasyQ assay,
bioMe´rieux, Boxtel, The Netherlands). In South Africa,
provincial and national guidelines recommend switching
drug regimens after two consecutive viral loads above 5,000
copies/ml, but patients were not necessarily switched when
they fulfilled these criteria.
All treatment, clinic consultations, and laboratory work are
free of charge. In both sites patients receive counselling and
adherence support. Patients on HAART who miss appoint-
ments are contacted where possible, and if required, traced
through home visits. More details on the Khayelitsha and
Gugulethu cohorts are given elsewhere [8,9].
Swiss HIV Cohort Study
Set up in 1988, the Swiss HIV Cohort Study is a national
prospective cohort study of HIV-infected patients followed
up at outpatient departments of five University hospitals
(Basel, Bern, Geneva, Lausanne, and Zurich) and two
Cantonal hospitals (Lugano and St. Gallen) in Switzerland.
A comparison with official AIDS notifications and deaths
indicated that about 70% of all patients living with AIDS in
Switzerland participate in the study [10].
Data collection and study procedures are standardised.
Detailed information on demographics, mode of HIV
acquisition, risk behaviours, clinical events, laboratory re-
sults, and treatments is collected at registration and then at
intervals of 6 mo. HIV-1 RNA (Roche Amplicor HIV-1
Monitor assay), CD4 counts, and other laboratory parameters
are measured at least every 3 mo. Clinical AIDS diagnoses
(Centers for Disease Control and Prevention [CDC] stage C)
are recorded by the treating physicians on the basis of the
1993 CDC criteria [11]. The decision to change therapy was
informed by the International AIDS Society-USA guidelines.
All services, including antiretroviral therapy and laboratory
testing, are covered by compulsory health insurance. More
details on the SHCS are given elsewhere [12,13].
Eligibility Criteria and Definitions
The same eligibility criteria were applied to patients in
Switzerland and South Africa. All treatment-naı¨ve patients
who started HAART at any point since 2001 (the year when
HAART became available in the two South African sites), had
at least one day of follow-up, and were aged 16 y or older
were included. Patients from Switzerland who acquired HIV
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through intravenous drug use were excluded from the
analysis because they are a group that is not represented in
the South African cohorts. In the South African cohorts HIV
transmission information is not routinely recorded, but most
patients were infected through heterosexual contacts.
HAART was defined as a combination of at least three
antiretroviral drugs. The type of regimen was defined as PI-
based (two NRTIs and one PI), NNRTI-based (two NRTIs and
one NNRTI), and other. Boosted PIs are counted as one drug.
The stage of disease was classified as less advanced (CDC stage
A/B, WHO stage I/II) or advanced (CDC stage C, WHO stage
III/IV).
Ethical Approval and Laboratory Quality Assurance
The local ethics committees of all seven study sites that
participate in the SHCS approved the study, and written
informed consent was obtained from all participants. Data
collection in the townships Khayelitsha and Gugulethu, South
Africa, as well as participation of these studies in the
Antiretroviral Treatment in Lower Income Countries Col-
laboration (ART-LINC) collaboration of IeDEA, were ap-
proved by the ethics committee of the University of Cape
Town, which did not require informed consent. All labo-
ratories involved in South Africa and Switzerland participate
in quality assurance programmes.
Endpoints
The following endpoints were considered: time to first
treatment change (overall and by reason for change),
virologic suppression (defined as HIV-1 RNA 500 copies/
ml), viral rebound (defined as HIV-1 RNA above 500 copies/
ml) after having achieved viral suppression, CD4 response,
and death from all causes. Viral rebound is usually defined as
two consecutive values above a given threshold. In our
analysis we used a single value, as the measurement frequency
differed between settings. In a sensitivity analysis we used two
consecutive values above 500 copies/ml. The threshold of 500
copies/ml was chosen because assays of different sensitivities
were used during the study period. Regimen change was
defined as any change to the treatment regimen, including
interruption and discontinuation, but excluding dosage
adjustments. The treating physician indicated the reason
for regimen changes, and these reasons were classified as
failure (virologic, immunologic, or clinical), toxicity, and
other. Specific definitions of reasons for regimen change,
including, for example, lactic acidosis, were not standardised
across sites. The severity of toxicities was not assessed.
Finally, we determined the proportion of initial regimens
that complied with the national South African guidelines or,
in the case of Switzerland, the International AIDS Society–
USA guidelines current at the time of starting HAART.
Statistical Analysis
We used an ‘‘intent-to-continue-treatment’’ approach and
thus ignored changes to treatment, including treatment
interruptions and terminations for virological endpoints
and death. Time was measured from the start of HAART or
from the first viral load measurement of 500 copies/ml or
below to the time the outcome occurred, the time of the last
follow-up visit, or 2 y after baseline, whichever came first. A
patient was considered lost to follow-up if the time between
the last visit of the patient and the closing date of the cohort
was longer than 1 y. Only patients who potentially had 1 y of
follow-up were included in the analysis of loss from follow-
up.
We used Kaplan–Meier graphs and Cox proportional
hazard models (for mortality and first treatment change)
and logistic regression (for viral response and viral rebound)
to estimate hazard ratios (HRs) and odds ratios (ORs) of
endpoints occurring, in comparing the two South African
cohorts with the Swiss cohort. For mortality, a separate model
was fitted for the first 3 mo after starting HAART (the period
with the highest mortality [14]) and for months 4–24. Since
background mortality differs between the two settings, we
compared expected mortality rates in Switzerland and South
Africa. We obtained estimates of non-HIV-related back-
ground mortality by sex and age group from the Global
Burden of Disease project [15,16], and used these rates to
calculate expected numbers of deaths in the two South
African cohorts. Similarly, we used rates available from the
Swiss Federal Statistical Office to calculate expected deaths
for the Swiss cohort.
For viral response the first viral load measurement within
6–12 mo after baseline was classified into 500 copies/ml
(virologic suppression) or .500 copies/ml. We used logistic
regression instead of a time-to-event approach, because the
frequency and timing of viral load measurements differed
between the two settings. Analyses were adjusted for baseline
CD4 count, HIV-1 viral load, stage of disease, sex, and age.
We calculated the rate of changing the first treatment
regimen by reason of change and time periods (1–3 mo, 4–6
mo, 7–12 mo, and 13–24 mo) by dividing the number of
patients developing the event by the number of person-years
at risk. We used Poisson regression to calculate confidence
intervals (CIs) for rates. Cause-specific cumulative incidences
were calculated applying a competing risk approach [17,18].
We used competing risk Cox regression as described by Lunn
and McNeil [19] to jointly analyze treatment change due to
failure, intolerance, and other reasons. This analysis was
adjusted for the same variables as above.
All analyses were performed using Stata version 9.2. Results
are presented as Kaplan–Meier probabilities, rates per 100
person-years, and HRs or ORs, with 95% CIs.
Results
Patient characteristics
A total of 3,364 patients—2,348 from Khayelitsha and
Gugulethu and 1,016 from the Swiss HIV Cohort Study—were
observed for 2,362 and 1,564 person-years, respectively. The
median observation time (taking censoring after 2 y into
account) was 0.7 y (interquartile range [IQR] 0.3–1.3 y) for
Gugulethu, 1.0 years (0.5–1.5 y) for Khayelitsha and 2.0 y (1.1–
2.0 y) for the Swiss cohort. Table 1 shows the characteristics of
patients at the time of treatment initiation. The patients in
the South African cohorts were younger, more likely to be
female, and in more advanced stages of the infection: the
median baseline CD4 count was 80 cells/ll compared to 204
cells/ll in the Swiss cohort, and 2,126 (90.6%) and 188
(18.5%), respectively, were in CDC stage C or WHO stage III/
IV. In South Africa the number of patients starting HAART
almost doubled every year from 79 in 2001 to 509 in 2003,
whereas in Switzerland the number of patients starting
HAART remained fairly constant since 2001.
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In Khayelitsha and Gugulethu over 95% of patients were
treated with one of four NNRTI-based first-line regimens
whereas in Switzerland 36 different regimens were used
(Table 1). The most commonly used regimens in South Africa
were stavudine/lamivudine (d4T/3TC) in combination with
efavirenz (EFV) (39.1%) or nevirapine (NVP) (33.2%). In
Switzerland the most frequent regimens were zidovudine/
lamivudine (AZT/3TC) in combination with either EFV (n ¼
304, 29.9%) or boosted lopinavir (LPV) (n ¼ 202, 19.9%) or
nelfinavir (NFV) (n ¼ 99, 9.7%). Stavudine (d4T) was used in
35 patients (3.4%) only. In South Africa 2,339 (99.6%) of
patients started with a regimen that was in accordance with
guidelines, compared to 966 (95.1%) of patients in Switzer-
land. In Switzerland 45 patients (4.5%) received regimens that
may have been chosen because of primary resistance or as
part of a study, and five patients (0.5%) received regimens
that clearly violated guidelines.
Changes to First-Line Regimens
Changes to the initial regimen during the first 2 y of
HAART were considerably more frequent in Switzerland
than in South Africa: 539 patients (53.1%) compared to 514
patients (21.9%) experienced at least one change during the
first 2 y of HAART. Substitutions of one drug were the most
frequent change both in Switzerland (274, 50.8%) and South
Africa (328, 63.8%). Figure 1 shows rates of any type of
change during months 1–3, 4–6, 7–12, and 13–24 along with
the estimated cumulative probability of change, by reason for
changing regimens: toxicity, failure, or other reasons. The
cumulative probability of change at 2 y due to toxicity was
23.8% (95% CI 21.0%–26.7%) in Switzerland compared to
11.7% (95% CI 10.0%–13.5%) in Khayelitsha and Gugulethu.
In contrast, the probability of changes due to failure was
similar in Switzerland and South Africa: 5.1% (95% CI 3.7%–
6.8%) and 3.9% (2.5%–5.6%), respectively. In patients who
were switched for failure, the median log10 HIV viral load
values at the time of treatment switch due to failure was 4.4
log10 copies/ml in South Africa (n¼31) and 3.4 log10 copies/ml
in Switzerland (n ¼ 39) (p , 0.001 for difference). In South
Africa all patients who switched for failure had detectable
viral loads, whereas in Switzerland ten patients (29%) had
viral loads 500 copies/ml. An estimated 30.9% (95% CI
27.7%–34.1%) of patients had changed regimens for other
reasons in Switzerland compared to 14.1% (12.1%–16.3%) in
South Africa.
In both settings toxicity was the dominant reason for
treatment change in the first 3 mo, but rates were consid-
erably higher in Switzerland than in South Africa: 53 per 100
person-years (95% CI 44–63) compared to 21 per 100 person-
years (17–25). Other reasons dominated from month 4
onwards, again with higher rates of change in Switzerland.
Treatment failure as reason for drug changes was rare in both
settings. Table 2 compares reasons for regimen change in
more detail. For toxicity the most notable difference relates
to elevated lactate levels and lactic acidosis: in Khayelitsha
and Gugulethu 32 (13.4%) of all regimen changes due to
toxicities were due to lactic acidosis (associated with d4T in
31 patients). In the Swiss study no patient changed the initial
regimen due to elevated lactate levels. Treatment changes due
to abdominal and gastrointestinal toxicity, including liver
toxicity, were more common in Switzerland than in South
Table 1. Baseline Characteristics of Patients Starting HAART in Khayelitsha and Gugulethu, South Africa and the Swiss HIV Cohort Study
Category Subcategory South African Cohorts Swiss HIV Cohort
Patients, n — 2,348 1,016
Females, n (%) 1,663 (71%) 333 (33%)
Age, y, median (IQR) — 32.7 (28.5–38.2) 38.3 (31.7–46.1)
CD4 cell count, cells/ll, median (IQR) — 80 (30–138) 204 (122–291)
CD4 cell count, number missing (%) — 123 (5.2%) 50 (4.9%)
HIV-1 viral load, log10 copies/ml, median (IQR) — 5.1 (4.6–5.5) 5.0 (4.5–5.5)
HIV-1 viral load, number missing (%) — 288 (12.3%) 53 (5.2%)
Clinical stage: CDC stage C, WHO stage III/IV, n (%) — 2,126 (90.6%) 188 (18.5%)
Duration of follow-up (years)a, median (IQR) — 0.9 (0.5–1.5) 2.0 (1.1–2.0)
Number of patients starting HAART in year, n (%) 2001 79 (3.4%) 179 (17.6%)
2002 246 (10.5%) 204 (20.1%)
2003 509 (21.7%) 185 (18.2%)
2004–2006b 1,514 (64.5%) 448 (44.1%)
Initial HAART regimen, n (%) 2 NRTIs þ 1 NNRTI 2,339 (99.7%) 470 (46.3%)
2 NRTIs þ 1 PI 9 (0.4%) 449 (44.2%)
Other 0 97 (9.6%)
Four most commonly used initial HAART regimens, n (%) 3TC D4T EFV 918 (39.1%) —
3TC D4T NVP 780 (33.2%) —
3TC AZT EFV 425 (18.1%) —
3TC AZT NVP 216 (9.2%) —
3TC AZT EFV — 304 (29.9%)
3TC AZT LPV/r — 202 (19.9%)
3TC AZT NFV — 99 (9.7%)
3TC TNV EFV — 65 (6.4%)
Initial HAART regimens used to treat 95% of patients, n — 4 36
Patients using initial HAART regimens recommended by guidelines, % — 95.1 99.6
aCensored after 2 y.
bRecruitment not completed for the years 2005/06.
doi:10.1371/journal.pmed.0050148.t001
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Africa. Changes due to other reasons were also more frequent
in Switzerland. The predominant other reasons for changing
first-line regimens in South Africa were pregnancy and
tuberculosis. In Switzerland changes due to patient requests
were common.
Virologic Response, Rebound, CD4 Response, and
Mortality
The frequency of HIV-1 RNA measurements differed in the
two settings (Figure 2). The median time to the first HIV-1
RNA determination was 3.1 mo (interquartile range [IQR]
2.8–3.7 mo) in Khayelitsha and Gugulethu compared to 1.0
mo (0.7–1.5 mo) in the Swiss study. During follow-up HIV-1
RNA was measured at regular time intervals in South Africa
(median 3.9 mo, IQR 3.2–6.0 mo) whereas in Switzerland the
time intervals were not well defined (2.9 mo, 1.9–3.4 mo). A
similar picture was evident for CD4 counts (unpublished
data). Kaplan-Meier plots show that in both settings most
patients suppressed HIV-1 RNA to 500 copies/ml or less
(Figure 3, top graph) within one year: 96.0% (95% CI 95.1%–
96.9%) of patients in the townships and 95.5% (94.0%–
96.7%) in the Swiss cohort. The proportion of patients with
viral load values 500 copies/ml at different time points was
around 90% up to 2 y in both Switzerland and South Africa.
Among the 2,644 patients who suppressed viral replication
to 500 copies/ml (1,716 in South Africa and 928 in
Switzerland), the probability of a viral rebound at 2 y after
suppression was 25.5% (95% CI 22.1%–29.3%) in South
Africa and 27.1% (23.9%–30.7%) in Switzerland (Figure 3,
middle graph). When analyses were repeated with two
consecutive measurements above 500 copies/ml, the rate of
viral rebound was slightly higher in Switzerland than in South
Africa, which is expected considering the higher measure-
ment frequency in Switzerland. During the 2 y the median
CD4 count increased from 80 cells/ll at baseline (IQR 30–138)
to 372 cells/ll (260–497) in South Africa and from 204 cells/ll
(122–291) to 449 (310–607) in Switzerland. Patients starting
HAART with lower CD4 cell counts tended to have lower
values throughout the study period, both in South Africa and
Switzerland.
Mortality was substantially higher in South Africa than in
Switzerland during the first months of HAART (Figure 3,
bottom graph). Cumulative mortality at 6 mo was 8.6% (95%
CI 7.5%–9.8%) and 0.9% (0.5%–1.8%), respectively. The
proportion of patients lost to follow-up was similar: by 1 y,
3.5% (95% CI 2.5%–4.7%) of patients in Khayelitsha and
Gugulethu and 3.2% (2.2%–4.7%) of patients in the Swiss
cohort were lost to follow-up.
Univariable and Multivariable Analyses
The results from univariable and multivariable logistic and
Cox models comparing the South African cohorts with the
Swiss cohort are presented in Table 3. For the three
endpoints change from first-line regimen, virologic response
and viral rebound, adjusting the models for sex and age, CD4
cell count, HIV-1 RNA, and stage of disease at baseline had
only modest effects on HRs and ORs. The adjusted HRs
comparing South Africa with Switzerland for treatment
change due to failure, intolerance, and other reasons were
0.25 (95% CI 0.12–0.50), 0.44 (0.32–0.60), and 0.30 (0.22–0.40)
respectively, but there was little evidence for a difference in
virologic response and viral rebound (Table 3). In contrast,
HRs for the mortality endpoints were attenuated consider-
ably in multivariable analysis: the adjusted HRs were 5.90
(95% CI 1.81–19.21) during months 1–3 and 1.77 (0.90–3.50)
during months 4–24. The expected non-HIV-related mortal-
ity rate was 28.1 per 10,000 person-years in the South African
cohorts compared to 13.3 in the Swiss cohort, for a rate ratio
of 2.11 (95% CI 1.10–4.06).
Discussion
This comparative study of patients starting HAART in
South Africa and Switzerland found that the initial virologic
response was similar, despite profound differences in patient
Figure 1. Rates and Kaplan-Meier Plots of First Treatment Change Due to
Toxicity, Failure, and Other Reasons in Khayelitsha and Gugulethu, South
Africa and the Swiss HIV Cohort Study
Dots indicate rates during months 1–3, 4–6, 7–12, and 13–24 with 95%
CIs; lines indicate the estimated proportion of patients changing their
first-line regimen. ‘‘Other reasons’’ (bottom graph) include mainly
treatment changes due to tuberculosis and pregnancy in South Africa
and changes due to patients’ wishes or physicians’ decisions in
Switzerland.
doi:10.1371/journal.pmed.0050148.g001
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characteristics and the approach to antiretroviral therapy,
and different viral strains causing the epidemics in the two
countries. Compared to South Africa, about twice as many
changes to the treatment regimen were recorded in Switzer-
land during the first two years. Mortality was higher in South
Africa than in Switzerland, particularly during the first three
months of HAART.
Public Health and Individualised Approaches to HAART
In South Africa, where the prevalence of HIV-1 subtype C
infection in the general population is estimated at 19%, the
Department of Health published detailed treatment guide-
lines for adults and children in 2004 [6], with the objective of
providing access to all patients in need. All patients start a
regimen consisting of a recommended NRTI backbone and
either EFV or NVP. In December 2006, an estimated
1,000,000 people in South Africa needed HAART, and
325,000 were receiving it [5]. In contrast, in Switzerland the
prevalence of HIV-1 is below 1% and mainly of subtype B,
HAART is covered by the compulsory basic health insurance
package, and access is therefore universal. Care is highly
individualised and delivered by specialists in HIV medicine.
The choice of the initial regimen is influenced by several
factors, including convenience, viral resistance to treatment,
potential side effects, and physician and patient preferences.
In both countries the provision of HAART has been found to
be cost-effective from a health services and societal perspec-
tive [20–22].
Antiretroviral Anarchy?
There has been concern that unregulated use of antire-
troviral drugs, interruptions in drug supplies, and the lack of
monitoring of treatment response in sub-Saharan Africa
might lead to ‘‘antiretroviral anarchy’’ and the emergence of
viral resistance [23]. For example, in Abidjan, Coˆte d’Ivoire,
39 (57%) of 68 patients who had relied on friends or relatives
in Europe or the United States for antiretroviral drugs before
a HAART programme was established had mutations in their
Table 2. Reasons for Change of the First HAART Regimen in the First Two Years of Treatment in Khayelitsha and Gugulethu, South
Africa and the Swiss HIV Cohort Study
Reason Details South African Cohorts (n ¼ 514) Swiss Cohort (n ¼ 539)
Patients, n (%) Patients, n (%)
Toxicity Any 238 (46.3%) 220 (40.8%)
Peripheral neuropathy 46 (8.9%) 53 (9.8%)
Gastrointestinal, including liver 37 (7.2%) 64 (11.9%)
Haematological 36 (7.0%) 20 (3.7%)
Lactic acidosis 32 (6.2%) 0 (0%)
Hypersensitivitya 30 (5.8%) 34 (6.3%)
Lipodystrophy 6 (1.2%) 12 (2.2%)
Dislipidaemia 4 (0.8%) 5 (0.9%)
Nephrological 0 (0%) 7 (1.3%)
Not specified 47 (9.1%) 25 (4.6%)
Failure Virologic, immunologic, or clinical 31 (6.0%) 39 (7.2%)
Other —b 244 (47.5%) 257 (47.7%)
Unknown — 1 (0.2%) 23 (4.3%)
aAny type of hypersensitivity in Switzerland, rash in South Africa.
bIn South Africa ‘‘other’’ reasons mainly included contraindications related to tuberculosis or pregnancy (167 patients); in Switzerland physician decisions (including contraindications,
changes in guidelines, etc.; 107 patients) and patient requests (85 patients).
doi:10.1371/journal.pmed.0050148.t002
Figure 2. Frequency of Viral Load Measurements in Khayelitsha and
Gugulethu, South Africa and the Swiss HIV Cohort Study
The frequency was standardized to the total number of measurements in
each setting.
doi:10.1371/journal.pmed.0050148.g002
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virus associated with resistance to at least one drug [24].
Similar data were reported from Libreville, Gabon [25]. The
development of resistance is closely linked to incomplete
adherence to therapy, and several studies have shown that
good adherence can be achieved in resource-limited settings
[26–28]. The overall virologic response observed in this study
suggests that adherence was good in the two South African
townships (the delay in reaching viral load values below 500
copies/ml in South Africa is probably explained by the less-
frequent viral load determinations in the township cohorts
compared to Switzerland). Therefore, our results indicate
that antiretroviral anarchy has been prevented in township
ART programmes in South Africa.
In industrialized settings, a substantial proportion of new
infections now involve strains resistant to one or more drugs
[29]. Viral resistance is rare in South Africa at present [30],
but is bound to increase in the future. WHO monitors drug
resistance at sentinel sites in South Africa and elsewhere [3].
The use of single-dose NVP to prevent mother-to-child
transmission of HIV may increase resistance levels, but the
implications for treatment are a matter of debate and the
subject of ongoing studies [31].
Considering the large number of first-line regimens used in
Switzerland, and the high rate of changes to these regimens,
one might argue that antiretroviral anarchy may in fact be
more prevalent in Switzerland than in South Africa. However,
we found that 95% of patients used regimens that were in
accordance with the International AIDS Society–USA guide-
lines in place during this period. Few regimens violated the
current guidelines. Nevertheless, a more standardised ap-
proach to the choice of the first-line regimen and monitoring
of viral load could probably reduce costs in Switzerland
without compromising the effectiveness of HAART.
Treatment Changes
Treatment changes that were reported to be due to toxicity
in the first 3 mo of treatment were more frequent in
Switzerland than in South Africa, despite the fact that in
Switzerland more drugs, and more drugs with a more
favourable adverse effects profile, are available. The type of
toxicities leading to treatment changes were fairly similar in
the two settings, with the exception of symptomatic hyper-
lactataemia or lactic acidosis, which was recorded in 32
patients in South Africa but not observed in Switzerland. This
difference is not surprising in light of the widespread use of
stavudine in South Africa but not in Switzerland. In South
Africa few patients switched because of lipodystrophy,
despite the widespread use of stavudine, possibly because
follow-up was relatively short. Indeed, a previous analysis of
the Khayelitsha and Gugulethu cohorts showed that drug
substitutions due to lipodystrophy occurred mainly after the
first year of treatment [32]. We stress that our analysis was
restricted to treatment changes attributed to toxicities: we
did not assess the overall incidence of toxicities nor the
severity of adverse events.
Early Mortality
Patients in South Africa started therapy with much more
pronounced immunodeficiency than did those in Switzer-
land, reflecting the large number of patients in great need of
treatment during the scale-up of HAART in South Africa. In
line with a previous collaborative analysis [14], the higher
mortality in the South African townships was probably only
partly explained by lower CD4 cell counts and more advanced
clinical stage at treatment initiation. It seems likely that
specific comorbidities, including invasive bacterial and fungal
infections, are important in this context. For example, an
Figure 3. Kaplan Meier Plots of Virologic Response, Viral Rebound, and
Mortality in Khayelitsha and Gugulethu, South Africa and the Swiss HIV
Cohort Study
Viral rebound is defined as having a HIV-1 RNA .500 copies/ml after a
viral load 500 copies/ml.
doi:10.1371/journal.pmed.0050148.g003
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earlier analysis of the Gugulethu data showed that six (27%)
of the 22 deaths that occurred during the first 3 mo were due
to cryptococcal disease, with a clinical course suggestive of
immune reconstitution disease [33].
Unfortunately, causes of death are not recorded system-
atically in the South African cohorts. A study from rural
Uganda showed that a positive serum cryptococcal antigen
was associated with substantially increased early mortality
(adjusted relative risk 6.6; 95% CI 1.9–12.6) [34]. The
corresponding relative risk for active tuberculosis was 4.4
(95% CI 1.2–15.4) [34]. Clinical trials in South Africa and
elsewhere will help identify strategies to reduce mortality,
including, for example, trials of HAART initiation in HIV–TB
coinfected patients [35] and isoniazid preventive therapy in
patients receiving HAART [36]. Limited access to diagnostic
tests, procedures, and drugs to diagnose and treat opportun-
istic illnesses, including access to intensive care, may also have
contributed to the higher mortality in the South African
townships.
After the first few months of HAART, mortality was low in
both the South African and Swiss cohorts. The higher
mortality in South Africa during this period probably reflects
a higher (non-HIV-related) background mortality in South
Africa. This interpretation is supported by our comparison of
mortality in Switzerland with non-HIV-related mortality in
South Africa. South African national HAART programme
still bases its treatment guidelines on the 2002 WHO
guidelines, which recommend HAART only for patients with
WHO stage IV disease or a CD4 cell count of less than 200
cells/ll [37]. These recommendations were revised in 2003
and now state that in patients with WHO stage III disease,
treatment should be considered when the CD4 count is below
350 cells/ll and initiated before the CD4 count drops to below
200 cells/ll [38]. Recent analyses from Cape Town showed
high mortality before HAART is started or before a formal
AIDS diagnosis is made [39–41]. Taken together, there is
strong evidence that public health strategies to increase
access in South Africa should be further promoted. A recent
analysis of the Swiss cohort showed that in Switzerland, late
presentation is the reason for late initiation of HAART: once
the diagnosis is made, uptake of HAART is fast [42].
Strengths and Limitations of the Study
All patients in this study were treatment-naı¨ve at the start
of HAART, and results are therefore not affected by previous
antiretroviral therapy.
The two South African township programmes were part of
the first public HAART programmes in Southern Africa and
are typical of many sites involved in the scale-up of HAART
in this region. Scale-up is reflected in the rapid increase in
the number of patients starting therapy during the study
period. Our study did not, however, include the private sector
in South Africa, and no comparison has been made between
the overall quality of medical care to support HAART and
HIV disease management that is likely to have an important
impact on mortality. The SHCS was one of the first HIV
cohort studies worldwide [12], and it includes all major HIV
outpatient clinics as well as a number of large private
practices. It is estimated that about 40% of all patients with
HIV and about 70% of patients with AIDS are included [10].
A limitation of our study is that although the reasons for
changes in therapy were assessed prospectively, this was not
done using the same, standardised instrument and definitions
in South Africa and Switzerland. The attribution of the causes
for treatment change is further complicated by the fact that
causes are not independent: a patient might want to change
therapy due to side effects, or side effects can cause problems
with adherence, which then leads to treatment failure.
The rate of loss to follow-up was low: in both settings
patients who missed appointments were contacted and, if
required, traced. However, follow-up information for the
South African sites is limited due to the continuous scale-up:
i.e., the majority of patients were registered only recently and
were thus followed only over a short period of time. These
patients will, by definition, not be lost to follow-up.
Continued follow-up of patients in South Africa is needed
to allow comparisons of treatment responses over longer
periods of time.
Table 3. Unadjusted and Adjusted HRs and ORs for Study Endpoints, Comparing Khayelitsha and Gugulethu, South Africa, with the
Swiss HIV Cohort Study
Study Endpoints Number of Patients, South
Africa/Switzerland
Number of Events, South
Africa/Switzerland
Unadjusted HRs or
ORs (95% CI)
p-Value Adjusteda HRs
or ORs (95% CI)
p-Value
First treatment changed 1,972/959 514/539 — — — —
First treatment change
due to failure
— 31/39 0.33 (0.20–0.53) ,0.001 0.25 (0.12–0.50) ,0.001
First treatment change
due to intolerance
— 238/220 0.43 (0.36–0.52) ,0.001 0.44 (0.32–0.60) ,0.001
First treatment change
due to other reasons
— 244/257 0.37 (0.31–0.45) ,0.001 0.30 (0.22–0.40) ,0.001
Viral suppressionb 1,175/810 1,074/735 1.09 (0.79–1.48) 0.61 1.14 (0.67–1.93) 0.63
Viral rebound 862/783 74/52 1.32 (0.91–1.91) 0.14 1.26 (0.68–2.31) 0.46
Mortality (months 1–3) 1,972/959 118/4 14.60 (5.39–39.54) ,0.001 5.90 (1.81–19.21) 0.003
Mortality (months 4–24) 1,823/912 85/23 2.61 (1.64–4.15) ,0.001 1.77 (0.90–3.50) 0.10
HRs are given for mortality and treatment change, ORs for initial viral response and viral rebound. The difference in the number of patients included in these analyses compared to the
total number of patients shown in Table 1 is explained by missing values in key variables.
aAnalyses were adjusted for sex, age, baseline CD4 cell count, baseline HIV viral load and stage of disease.
bHIV-1 RNA 500 copies/ml.
doi:10.1371/journal.pmed.0050148.t003
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Conclusions
A public-health approach to HAART provision using a
limited repertoire of drugs and relatively few viral load
measurements resulted in virologic treatment outcomes in
townships in South Africa that were similar to outcomes in
Switzerland. Our study also shows that many patients would
benefit from earlier initiation of therapy, particularly in
South Africa.
Supporting Information
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French by Claire Graber
Found at doi:10.1371/journal.pmed.0050148.sd001 (26 KB DOC).
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Editors’ Summary
Background. Acquired immunodeficiency syndrome (AIDS) has killed
more than 25 million people since the first reported case in 1981, and
more than 30 million people are now infected with the human
immunodeficiency virus (HIV), which causes AIDS. HIV destroys immune
system cells (including CD4 cells, a type of lymphocyte), leaving infected
individuals susceptible to other infections. Early in the AIDS epidemic,
most HIV-infected people died within 10 years of becoming infected.
Then, in 1996, highly active antiretroviral therapy (HAART)—a combina-
tion of several antiretroviral drugs—was developed. Now, in resource-
rich countries, clinicians provide individually tailored care for HIV-
infected people by prescribing combinations of antiretroviral drugs
chosen from more than 20 approved medicines. The approach to
treatment of HIV in developed countries typically also includes frequent
monitoring of the amount of virus in patients’ blood (viral load), viral
resistance testing (to see whether any viruses are resistant to specific
antiretroviral drugs), and regular CD4 cell counts (an indication of
immune-system health). Since the implementation of these interven-
tions, the health and life expectancy of people with HIV has improved
dramatically in these countries.
Why Was This Study Done? The history of HIV care in resource-poor
countries has been very different. Initially, these countries could not
afford to provide HAART for their populations. In 2003, however,
governments, international agencies, and funding bodies began to
implement plans to increase HAART coverage in developing countries.
By December 2006, more than a quarter of the HIV-infected people in
low- and middle-income countries who urgently needed treatment were
receiving HAART. However, instead of individualized treatment, HAART
programs in developing countries follow a public-health approach
developed by the World Health Organization. That is, drug regimens,
clinical decision-making, and clinical and laboratory monitoring are all
standardized. This public-health approach takes into account the realities
of under-resourced health systems, but is it as effective as the
individualized approach? The researchers addressed this question by
comparing virologic responses (the effect of treatment on the viral load),
changes to first-line (initial) therapy, and deaths in patients receiving
HAART in South Africa (public-health approach) and in Switzerland
(individualized approach).
What Did the Researchers Do and Find? The researchers analyzed data
collected since 2001 from more than 2,000 patients enrolled in HAART
programs in two townships (Gugulethu and Khayelitsha) in Cape Town,
South Africa, and from more than 1,000 patients enrolled in the Swiss HIV
Cohort Study, a nationwide study of HIV-infected people. The patients in
South Africa, who had a lower starting CD4 cell count and were more
likely to have advanced AIDS than the patients in Switzerland, started
their treatment for HIV infection with one of four first-line therapies, and
about a quarter changed to a second-line therapy during the study. By
contrast, 36 first-line regimens were used in Switzerland and half the
patients changed to a different regimen. Despite these differences, the
viral load was greatly reduced within a year in virtually all the patients
and viral rebound (an increased viral load after a low measurement)
developed within 2 years in a quarter of the patients in both countries.
However, more patients died in South Africa than in Switzerland,
particularly during the first 3 months of therapy.
What Do These Findings Mean? These findings suggest that the public-
health approach to HAART practiced in South Africa is as effective in
terms of virologic outcomes as the individualized approach practiced in
Switzerland. This is reassuring because it suggests that ‘‘antiretroviral
anarchy’’ (the unregulated use of antiretroviral drugs, interruptions in
drug supplies, and the lack of treatment monitoring), which is likely to
lead to the emergence of viral resistance, is not happening in South
Africa as some experts feared it might. Thus, these findings support the
continued rollout of the public-health approach to HAART in resource-
poor countries. Conversely, they also suggest that a more standardized
approach to HAART could be taken in Switzerland (and in other
industrialized countries) without compromising its effectiveness. Finally,
the higher mortality in South Africa than in Switzerland, which partly
reflects the many patients in South Africa in desperate need of HAART
and their more advanced disease at the start of therapy, suggests that
HIV-infected patients in South Africa and in other resource-limited
countries would benefit from earlier initiation of therapy.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050148.
 The World Health Organization provides information about universal
access to HIV treatment (in several languages) and on its
recommendations for a public-health approach to antiretroviral
therapy for HIV infection
 More details on the Swiss HIV Cohort Study and on the studies in
Gugulethu and Khayelitsha are available
 Information is available from the US National Institute of Allergy and
Infectious Diseases on HIV infection and AIDS
 HIV InSite has comprehensive information on all aspects of HIV/AIDS,
including detailed information about antiretroviral therapy and links to
treatment guidelines for various countries
 Information is available from Avert, an international AIDS charity, on
HIV and AIDS around the world and on providing AIDS drug treatment
for millions
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